Health Care [ 12/12 ] | Health Care Providers & Services [ 26/74 ]
NASDAQ | Common Stock
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.
In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | -0.62 Increased by +27.06% | -0.50 Decreased by -23.06% |
| Nov 6, 24 | -0.88 Decreased by -20.55% | -0.74 Decreased by -18.92% |
| Aug 7, 24 | -0.84 Decreased by -25.37% | -0.74 Decreased by -13.51% |
| May 9, 24 | -0.94 Increased by +27.69% | -0.85 Decreased by -10.59% |
| Feb 22, 24 | -0.85 Increased by +37.50% | -0.86 Increased by +1.16% |
| Nov 6, 23 | -0.73 Increased by +48.23% | -0.95 Increased by +23.16% |
| Aug 3, 23 | -0.67 Increased by +47.24% | -1.18 Increased by +43.22% |
| May 9, 23 | -1.30 Decreased by -7.44% | -1.32 Increased by +1.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 201.81 M Increased by +30.16% | -111.01 M Increased by +40.65% | Decreased by -55.00% Increased by +54.40% |
| Sep 30, 24 | 191.48 M Increased by +33.87% | -107.75 M Decreased by -25.15% | Decreased by -56.28% Increased by +6.52% |
| Jun 30, 24 | 177.24 M Increased by +29.23% | -102.63 M Decreased by -41.03% | Decreased by -57.91% Decreased by -9.13% |
| Mar 31, 24 | 168.49 M Increased by +30.90% | -114.98 M Increased by +13.89% | Decreased by -68.24% Increased by +34.22% |
| Dec 31, 23 | 155.05 M Increased by +22.19% | -187.04 M Decreased by -33.67% | Decreased by -120.63% Decreased by -9.39% |
| Sep 30, 23 | 143.03 M Increased by +21.83% | -86.10 M Increased by +46.85% | Decreased by -60.20% Increased by +56.37% |
| Jun 30, 23 | 137.15 M Increased by +25.66% | -72.77 M Increased by +68.28% | Decreased by -53.06% Increased by +74.76% |
| Mar 31, 23 | 128.71 M Increased by +33.94% | -133.53 M Decreased by -8.36% | Decreased by -103.74% Increased by +19.10% |